Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers
W. Siljan (Drammen, Norway), J. Holter (Drammen, Norway), A. Michelsen (Oslo, Norway), S. Nymo (Oslo, Norway), J. Norseth (Bærum, Norway), E. Husebye (Drammen, Norway), T. Lauritzen (Drammen, Norway), T. Ueland (Oslo, Norway), T. Mollnes (Oslo, Norway), P. Aukrust (Oslo, Norway), L. Heggelund (Drammen, Norway)
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Siljan (Drammen, Norway), J. Holter (Drammen, Norway), A. Michelsen (Oslo, Norway), S. Nymo (Oslo, Norway), J. Norseth (Bærum, Norway), E. Husebye (Drammen, Norway), T. Lauritzen (Drammen, Norway), T. Ueland (Oslo, Norway), T. Mollnes (Oslo, Norway), P. Aukrust (Oslo, Norway), L. Heggelund (Drammen, Norway). Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers. 2622
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: